TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients’ own islet cell health.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 1927 First Avenue North, Birmingham,al 35203,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://tiximed.com/
- Keywords
- diabetes.
- HQ
- Birmingham, AL
Tiximed Questions
Tiximed's website is https://tiximed.com/
Tiximed's LinkedIn profile is https://www.linkedin.com/company/tiximed
Tiximed has
3 employees.
View email and phone details for 3
employees at Tiximed.
Tiximed's industry is
Biotechnology Research
Tiximed's top competitors are
Eli Lilly And Company,
Rtmbio,
Cmc-Rx Consultancy,
The Helmsley Charitable Trust,
Closing The Gaps,
Hart's Mobility Llc,
Kitalys Institute,
Theracosbio,
Abvance Therapeutics,
Kinexum Services Llc.
Tiximed's categories are Biotechnology Research
Tiximed's founding year is 2021
